Tech Center 1600 • Art Units: 1624 1625
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18564799 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | Non-Final OA | MERCK SHARP & DOHME LLC |
| 18029899 | COMPOUNDS WITH GLUCOCORTICOID SPARING EFFECTS AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18504244 | Tetrahydro-Pyrido-Pyrimidine Derivatives | Non-Final OA | Novartis AG |
| 18038579 | ENANTIOSELECTIVE ALKENYLATION OF ALDEHYDES | Non-Final OA | AMGEN INC. |
| 18078571 | DEUTERATED DERIVATIVES OF RUXOLITINIB | Non-Final OA | Sun Pharmaceutical Industries, Inc. |
| 17906604 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | Non-Final OA | Purdue Research Foundation |
| 17058390 | PRODRUGS OF FULVESTRANT | Non-Final OA | KASHIV BIOSCIENCES, LLC |
| 18044329 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | Final Rejection | AURIGENE ONCOLOGY LIMITED |
| 18558842 | Inhibitors of Tryptases and Their Use in Treating Allergies | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17603217 | COMPOUNDS WITH ANTIMALARIAL ACTIVITY | Final Rejection | UNIVERSITY OF PUERTO RICO |
| 18277765 | SMALL MOLECULE ALLOSTERIC MODULATORS OF CLASS B GPCR, THE PTHR, AND METHOD TO IDENTIFY THEM | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18017000 | IBOGAINE ANALOGS AS THERAPEUTICS FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 17938003 | KRATOM OPIOID DERIVATIVES FOR THE TREATMENT OF ALCOHOL USE DISORDER | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18004109 | Preparation Of A Pyrimidinyl-3,8-Diazabicyclo[3.2.1]Octanylmethanone Derivative And Salt Thereof | Non-Final OA | PFIZER INC. |
| 17855772 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS | Final Rejection | ALBERT EINSTEIN COLLEGE OF MEDICINE |
| 18221936 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | Final Rejection | Boehringer Ingelheim International GmbH |
| 18515890 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | Non-Final OA | INVENTISBIO CO., LTD. |
| 17923466 | GLUCOCORTICOID RECEPTOR MODULATORS | Final Rejection | TRUSTEES OF DARTMOUTH COLLEGE |
| 17627914 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES | Non-Final OA | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY |
| 18558159 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | Non-Final OA | XIZANG HAISCO PHARMACEUTICAL CO., LTD. |
| 17758660 | Preparation of Buprenorphine | Final Rejection | RIVER STONE BIOTECH APS |
| 18279219 | BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. |
| 18220874 | IONIZABLE LIPIDS FOR NANOMATERIALS | Non-Final OA | Beam Therapeutics Inc. |
| 18285323 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Non-Final OA | NERVIANO MEDICAL SCIENCES S.R.L. |
| 18004353 | SUCCINATE SALTS OF OCTAHYDROTHIENOQUINOLINE COMPOUND AND CRYSTALS THEREOF | Final Rejection | KISSEI PHARMACEUTICAL CO., LTD. |
| 17989103 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Non-Final OA | Enanta Pharmaceuticals, Inc. |
| 18026888 | METHOD FOR MASS-PRODUCING SODIUM TAURODEOXYCHOLATE | Non-Final OA | SHAPERON INC. |
| 18233390 | SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT | Non-Final OA | TEVA PHARMACEUTICALS INTERNATIONAL GMBH |
| 18274630 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED |
| 18009981 | ISOQUINOLINE COMPOUND, MANUFACTURING METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | Wuhan Institute of Virology, Chinese Academy of Science |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy